Skip to main content

Advertisement

SpringerLink
Log in

Malignant pleural mesothelioma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Despite innumerable trials of surgery, radiotherapy, and countless chemotherapeutic drugs, it is unclear whether any intervention has had a significant impact on more than a few highly selected patients with malignant pleural mesothelioma. Because most patients die of respiratory failure from extensive disease progression in the thorax, treatment usually includes attempts at local control. Unfortunately, radiotherapy is associated with significant complications in pleural mesothelioma, and surgery is feasible in only a small percentage of patients. Although there have been several single-institution reports of combined-modality therapy with extrapleural pneumonectomy, postoperative radiation, and chemotherapy in which prolonged survival has been observed, most patients with malignant pleural mesothelioma have locally advanced disease, advanced age, or comorbid medical illnesses that preclude aggressive surgery. Therefore, the use of a systemic anticancer agent is the only treatment option for most patients with malignant pleural mesothelioma.

Evaluation of effective chemotherapy regimens for this disease has been hampered by many factors. Because mesothelioma is an uncommon malignancy, most studies have enrolled small numbers of patients, and few trials have been randomized. The disease is heterogenous, yet until recently there was no single staging system that could reliably predict survival, nor is there a universally accepted set of prognostic criteria for selecting a uniform group of patients. Response assessment has been limited by the inherent difficulties of reproducibly measuring pleural-based disease. The real impact of systemic chemotherapy on the natural history of malignant mesothelioma is still uncertain because phase III trials comparing chemotherapy with best supportive care have not yet been completed.

Although nearly every class of cytotoxic agent has been evaluated in mesothelioma, response rates of greater than 20% have not been consistently demonstrated for any drug. The most active drug classes are the antifolates, the anthracyclines, and the platinums. Doxorubicin has historically been considered the gold-standard chemotherapy, although its true response rate is likely only 15%. The most active commercially available drug for mesothelioma so far appears to be gemcitabine. Although gemcitabine has a limited role as a single agent, it is quite active in combination with a platinating agent. The impressive 48% response rate reported for the combination of gemcitabine with cisplatin in a single phase II study has made this regimen the new standard of care for off-protocol treatment of this disease, although this trial still requires validation.

With the recent introduction of several new agents with definite activity in this disease, the therapeutic nihilism previously associated with malignant pleural mesothelioma is gradually being replaced by a cautious optimism. Early trials of angiogenesis inhibitors, gene therapy, and vaccines offer additional avenues for treatment. As we begin to incorporate these active new drugs with each other and in adjuvant and neoadjuvant treatment regimens, there is reason to believe that superior results for patients with malignant pleural mesothelioma can be achieved in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kindler HL, Vogelzang NJ: Mesothelioma. In Oncologic Therapies. Edited by Vokes EE, Golomb HM. Berlin: Springer-Verlag; 1999:635–651.

    Google Scholar 

  2. Baas P, Schouwink H, Zoetmulder FAN: Malignant pleural mesothelioma. Ann Oncol 1998, 9:139–149. An excellent overview of malignant pleural mesothelioma.

    Article  PubMed  CAS  Google Scholar 

  3. Boutin C, Rey F: Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 1993, 72:389–393.

    Article  PubMed  CAS  Google Scholar 

  4. International Mesothelioma Interest Group: A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995, 108:1122–1128. The new IMIG staging system for mesothelioma.

    Google Scholar 

  5. Boutin C, Rey F, Gouvernet J, et al.: Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer 1993, 72:394–404.

    Article  PubMed  CAS  Google Scholar 

  6. Sugarbaker DJ, Strauss GM, Lynch TJ, et al.: Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 1993, 11:1172–1178.

    PubMed  CAS  Google Scholar 

  7. Herndon JE II, Green MR, Chahinian AP, et al.: Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998, 113:723–731.

    PubMed  CAS  Google Scholar 

  8. Ong ST, Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996, 14:1007–1017. A comprehensive review of chemotherapy for malignant mesothelioma.

    PubMed  CAS  Google Scholar 

  9. Middleton GW, Smith IE, O’Brien ME, et al.: Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998, 9:269–273. The authors describe a phase II trial in which 62% of patients obtained an improvement in their symptoms with chemotherapy despite an objective response rate of only 20%.

    Article  PubMed  CAS  Google Scholar 

  10. Steele JPC, Evans MT, Tischkowitz MD, et al.: Vinorelbine is an active and well tolerated drug for the treatment of malignant mesothelioma: a phase II study. Proc Am Soc Clin Oncol 1999, 18:490a.

    Google Scholar 

  11. Byrne MJ, Davidson JA, Musk AW, et al.: Cisplatin and gemcitabine for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17:25–30. A report on one of the most active regimens for this disease.

    PubMed  CAS  Google Scholar 

  12. Lerner HJ, Schoenfeld DA, Martin A, et al.: Malignant mesothelioma: the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983, 52:1981–1985.

    Article  PubMed  CAS  Google Scholar 

  13. Solheim OP, Saeter G, Finnanger AM, et al.: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992, 65:956–960.

    PubMed  CAS  Google Scholar 

  14. Thodtmann R, Depenbrock H, Dumez H, et al.: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 1999, 17:3009–3016. The authors describe a phase I trial in which 38% of patients with malignant mesothelioma achieved an objective response.

    PubMed  CAS  Google Scholar 

  15. Calvert AH, Hughes AN, Calvert PM, et al.: Alimta in combination with carboplatin demonstrates clinical activity against malignant mesothelioma in a phase I trial. Proc Am Soc Clin Oncol 2000, 19:495a.

    Google Scholar 

  16. Fizazi K, Ducreux M, Ruffie P, et al.: Phase I, dose-finding and pharmacologic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 2000, 18:2293–2300.

    PubMed  CAS  Google Scholar 

  17. Fizazi H, Doubre H, Viala J, et al.: The combination of raltitrexed (’tomudex’) and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. Proc Am Soc Clin Oncol 2000, 19:578a.

    Google Scholar 

  18. Kindler HL, Millard F, Herndon JE, et al.: Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer, in press.

  19. van Meerbeeck JP, Baas P, Debruyne C, et al.: A phase II study of gemcitabine in patients with malignant pleural mesothelioma. Cancer 1999, 85:2577–2582.

    Article  PubMed  Google Scholar 

  20. Bischoff HG, Manegold C, Knopp M, et al.: Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol 1998, 17:464a.

    Google Scholar 

  21. Aversa SML, Favaretto AG: Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV. Clin Lung Cancer 1999, 1:1.

    Article  Google Scholar 

  22. van Meerbeeck J, Debruyne C, vanZandwijk N, et al.: Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996, 74:961–963.

    PubMed  Google Scholar 

  23. Vogelzang NJ, Herndon JE, Miller A, et al.: High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Ann Oncol 1999, 10:597–600.

    Article  PubMed  CAS  Google Scholar 

  24. Maksymiuk AW, Jung S-H, Marschke RF, et al.: Phase II trial of topotecan in pleural mesothelioma: a North Central Cancer Treatment Group (NCCTG) trial. Proc Am Soc Clin Oncol 1995, 14:435.

    Google Scholar 

  25. Nakano T, Chahinian AP, Shinjo M, et al.: Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II trial and pharmacokinetic profile. Cancer 1999, 85:2375–2384.

    Article  PubMed  CAS  Google Scholar 

  26. Kindler HL, Herndon JE, Vogelzang NJ, et al.: CPT-11 in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 9733). Proc Am Soc Clin Oncol 2000, 19:505a.

    Google Scholar 

  27. Belani CP, Adak S, Aisner S, et al.: Docetaxel for malignant mesothelioma: Phase II study of the Eastern Cooperative Oncology Group (ECOG 2595). Proc Am Soc Clin Oncol 1999, 18:474a.

    Google Scholar 

  28. Vorobiof DA, Chasen MR, Abratt RP, et al.: Phase II trial of single agent taxotere (T) in malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 2000, 19:578a.

    Google Scholar 

  29. Boutin C, Rey F, Viallat J-R, et al.: Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 1995, 108:754–758.

    PubMed  CAS  Google Scholar 

  30. Rusch VW, Rosenzweig K, Venkatraman ES, et al.: A prospective trial of surgical resection and high dose hemithoracic radiation for malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2000, 19:578a.

    Google Scholar 

  31. Sugarbaker D.J, Norberto JJ: Multimodality management of malignant pleural mesothelioma. Chest 1998, 113:61S-65S.

    PubMed  CAS  Google Scholar 

  32. Rusch VW, Venkatraman E: The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1996, 111:815–826.

    Article  PubMed  CAS  Google Scholar 

  33. Perez-Soler R, Walsh GL, Swisher SG, et al.: Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 1999, 18:421a.

    Google Scholar 

  34. Taub RN, Keohan ML, Vogelzang NJ, et al.: Phase II trial of Onconase (Ò) in patients (PTS) with advanced malignant mesothelioma (MM): analysis of survival. Proc Am Soc Clin Oncol 1999, 18:524a.

    Google Scholar 

  35. Vogelzang N, Taub R, Shin D, et al.: Phase III randomized trial of onconase (ONC) vs. doxorubicin (DOX) in patients (PTS) with unresectable malignant mesothelioma (UMM): analysis of survival. Proc Am Soc Clin Oncol 2000, 19:505a.

    Google Scholar 

  36. Ohta Y, Shridhar V, Bright RK, et al.: VEGF, VEGF Type C, and their receptors play an important role in angiogenesis and lymphangiogensis in human malignant mesothelioma tumors. Br J Cancer 1999, 81:54–61.

    Article  PubMed  CAS  Google Scholar 

  37. Kumar-Singh S, Vermeulen PB, Weyler J, et al.: Evaluation of tumor angiogenesis as a prognostic marker in malignant mesothelioma J Pathol 1997, 182:211–216.

    Article  PubMed  CAS  Google Scholar 

  38. Treat J, Kaiser L, Recio A, et al.: Adenoviral-mediated intrapleural HSVtk gene therapy (AdRSVtk) for malignant mesothelioma: a phase I clinical trial. Proc Am Soc Clin Oncol 1997, 16:433a.

    Google Scholar 

  39. Pass HI, Temeck BK, Kranda K, et al.: Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 1997, 4:628–633.

    Article  PubMed  CAS  Google Scholar 

  40. Carbone M, Pass HI, Rizzo P, et al.: Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 1994, 9:1781–1790.

    PubMed  CAS  Google Scholar 

  41. Xie YC, Hwang C, Overwijk W, et al.: Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen. J Natl Cancer Inst 1999, 91:169–175.

    Article  PubMed  CAS  Google Scholar 

  42. Raghavan D, Gianoutsos P, Bishop J, et al.: Phase II trial of carboplatin in the management of mesothelioma. J Clin Oncol 1990, 8:151–154.

    PubMed  CAS  Google Scholar 

  43. Zidar BL, Green S, Pierce HI, et al.: A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1988, 6:223–226.

    Article  PubMed  CAS  Google Scholar 

  44. Bajorin D, Kelsen D, Mintzer DM: Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat Rep 1987, 71:857–858.

    PubMed  CAS  Google Scholar 

  45. Chahinian AP, Antman K, Goutsou M, et al.: Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993, 8:1559–1565.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Oncology, University of Chicago Medical Center, 5841 S. Maryland Avenue, MC 2115, 60637, Chicago, IL, USA

    Hedy Lee Kindler MD

Authors
  1. Hedy Lee Kindler MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kindler, H.L. Malignant pleural mesothelioma. Curr. Treat. Options in Oncol. 1, 313–326 (2000). https://doi.org/10.1007/s11864-000-0047-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-000-0047-4

Keywords

Search

Navigation